Stay updated with breaking news from Compugen. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
DUBLIN--(BUSINESS WIRE)--The "Anti TIGIT Antibody Market Opportunity and Clinical Trials Insight 2024" report has been added to ResearchAndMarkets.com's offering.The report provides insights into the clinical trials and market dynamics of anti TIGIT antibodies. TIGIT (T cell immunoreceptor with Ig and ITIM domains)...
/PRNewswire/ -- The "Anti TIGIT Antibody Market Opportunity and Clinical Trials Insight 2024" report has been added to ResearchAndMarkets.com's offering. The...
/PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today...
Public accounts also for 2022-23 also reveal B.C.’s highest paid public executives
Truist Financial reissued their buy rating on shares of Compugen (NASDAQ:CGEN – Free Report) in a research note published on Wednesday, Benzinga reports. They currently have a $4.00 target price on the biotechnology company’s stock. Separately, StockNews.com started coverage on shares of Compugen in a report on Thursday, August 17th. They set a hold rating […]